WO2023161879 - CYTOTOXICITY TARGETING CHIMERAS FOR FIBROBLAST ACTIVATION PROTEIN-EXPRESSING CELLS
National phase entry is expected:
Publication Number
WO/2023/161879
Publication Date
31.08.2023
International Application No.
PCT/IB2023/051748
International Filing Date
24.02.2023
Title **
[English]
CYTOTOXICITY TARGETING CHIMERAS FOR FIBROBLAST ACTIVATION PROTEIN-EXPRESSING CELLS
[French]
CHIMÈRES CIBLANT LA CYTOTOXICITÉ POUR DES CELLULES EXPRIMANT DES PROTÉINES D'ACTIVATION DE FIBROBLASTES
Applicants **
GLAXOSMITHKLINE INTELLECTUAL PROPERTY DEVELOPMENT LIMITED
Inventors
DI MARCO, Christina Ng
SENDER, Matthew Robert
TURUNEN, Brandon
Priority Data
63/314,018
25.02.2022
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3125 | |
| EPO | Filing, Examination, Granting | 18824 | |
| Japan | Filing, Examination, Granting | 2667 | |
| South Korea | Filing, Examination, Granting | 3055 | |
| USA | Filing, Examination, Granting | 8590 |
Total:
36,261
The term for entry into the National Phase has expired. This quotation is for informational purposes only
Contact Us
Abstract[English]
The present disclosure relates to heterobifunctional molecules, referred to as cytotoxicity targeting chimeras (CyTaCs) or antibody recruiting molecules (ARMs) that are able to simultaneously bind a target cell-surface protein as well as an exogenous antibody protein. The present disclosure also relates to agents capable of binding to a receptor on a surface of a pathogenic cell and inducing the depletion of the pathogenic cell in a subject for use in the treatment of cancer.[French]
La présente divulgation concerne des molécules hétérobifonctionnelles, appelées chimères ciblant la cytotoxicité (CyTaC) ou des molécules de recrutement d'anticorps (ARM, « antibody recruiting molecule ») pouvant se lier simultanément à une protéine de surface cellulaire cible ainsi qu'une protéine d'anticorps exogène. La présente divulgation concerne également des agents aptes à se lier à un récepteur sur une surface d'une cellule pathogène et à induire la déplétion de la cellule pathogène chez un patient pour une utilisation dans le traitement du cancer.